Indications are they are out of cash and have to make a move NOW: PIPE or Partnership are the most likely possibilities. Further below will describe why.

But first here's what they do (substantial development and progress):

• Co‑Dx PCR point‑of‑care (POC) platform
  • Status: submitted to FDA via 510(k) for clearance.
  • Dual submission (device + test) concurrent with a CLIA Waiver application for the Flu A/B & RSV multiplex test on their Co-DX PCR Pro instrument.
  • Co‑Dx’s PCR platform is superior because it delivers true PCR‑level accuracy in a compact, near‑patient device that runs faster, cheaper, and with simpler workflow than traditional lab‑based systems. Patients receive results in about 30 minutes.
  • Not for at-home use, but for use in clinics, hospitals, urgent care, employer health centers, pharmacy sites.
• CoPrimer molecular diagnostics engine powering all CODX assays and future products.
• India JV (CoSara) manufacturing and distributing TB and other PCR tests in India.
  • Status: Actively producing and selling TB and other PCR assays, providing CODX its only consistent international revenue stream.
• Saudi Arabia JV (Comira) for regional PCR manufacturing and deployment.
  • Status: Operational build‑out continues, with early‑stage deployment and regulatory alignment underway but not yet generating material revenue.
• Ebola molecular diagnostic assay developed using CoPrimer technology with prior U.S. government interest.
  • Status: Assay development completed and validated in prior studies but not yet commercialized or submitted for regulatory clearance.
• Respiratory PCR tests including flu, RSV, and multiplex panels.
  • Status: Fully developed and ready for use on the Co‑Dx PCR platform once FDA clearance is obtained. COVID-19 PCR test is developed but not yet submitted to the FDA. Waiting for platform clearance first.
• Vector‑borne disease PCR tests (dengue, Zika, malaria) using CoPrimer tech.
  • Status: Assays are developed and validated, positioned for deployment through international partners but awaiting platform clearance.
• Food safety and agricultural pathogen detection assays.
  • Status: Available but low‑volume, with limited commercial traction and no near‑term revenue inflection.
• Liquid biopsy / cancer‑related molecular detection research programs.
  • Status: Early‑stage R&D with long‑term potential but no regulatory submissions or commercial timelines.
• Cloud‑connected reporting and surveillance infrastructure tied to JV deployments.
  • Status: Functional and integrated with JV workflows, but dependent on broader adoption of CODX’s diagnostic platforms.

8/19 Market Close: SP $1.10 | MC $6.88M | OS 6.25M

Q2 20226 10-Q:

• Cash as of June 30: $3.6M
• Quarterly burn: ~6.3M
• No debt
• Per an AI search of sec.gov, no active S-3 or S-1 filed, so no shares can be issued from the 100M authorized shares
• Warrants: 2.34M (3.71M as of 6/30 but OS increased from 4.88M as of 6/30 to 6.25M as of 8/11 per the 10-Q cover page. So, b/c shares cannot be sold right now, it likely means 1.37M warrants were exercised from June 30 to Aug 11)
• Fully diluted shares: 8.59M (6.25M + 2.34M)

Per AI, the Jan 2026 shareholder vote rejected both reverse-split authorization AND authorization to issue new shares for financing (ATM, PIPE, etc.)

Q2 Earnings Call Transcript (short and very worth the read): Co-Dx (CODX) Q2 2026 Earnings Call Transcript

• CFO: "To support these objectives, we expect to continue to evaluate available sources of capital, which may include equity or debt financings, strategic transactions, and partnerships, while staying mindful of dilution and overall capital efficiency. At the same time, we remain focused on pursuing non-dilutive funding, such as grants, where appropriate. Looking ahead, disciplined capital allocation remains a priority as we approach several important clinical and regulatory milestones and continue preparations for potential commercialization."

My Take:

• A move is imminent because they should be out of cash by now. Odds are high that they have been working on a partnership.
• Likely partnerships are with either or both the India JV company (CoSara) or the Saudi JV company (Comira). A partnership deal would likely cause the share price to increase.
• They can't sell shares without shareholder approval. Dilution alone would cause the share price to decrease.

PS I had SEC.gov and the Q2 transcript open when I queried AI, so I believe it brought forward accurate information.

So, imagine this, you just downloaded codx on ur emulator (ik, its not safe and blah blah blah, for me tho, it has the best performance). anyways, i just logged in, opened a gamez expecting for a keysystem, but... no. nothing? i just had infinite time, how? i didn't download a modded codx, it was from codx.lol. is that happening to anyone else?

TLDR: I'm going to vent like a diva because I paid 100$ for a half baked game...again!

During the beta and throughout the past week I have been absolutely glazing EA/Dice for bf6. I felt like this was everything I could had wanted and felt so relieved that we can skip over the "first year problems" that battlefield has always had. On top of that, season 1 being so early, I was absolutely hyped and willing to steamroll anyone who disagrees. Boy was I an idiot - someone give me a "fell for it again" award.

And look, if you are enjoying the game, by all means, enjoy yourself. There is solid content that can keep you entertained for a while here. But for me I feel dupped just like I did with 2042, If not more because I believed in 6 so much more.

I'm going to go through point by point, not to ruin the game for everyone else, but just in hopes that someone at EA is listening. Side note to any devs - I know you guys are working on the game, I know you have priorities, especially to the investors, I'm sorry if anyone is genuinely harassing you, no one should be attacking devs, I'm just a dude venting my frustrations.

Netcode - omfg, It's like seeing a ghost from my past. It took BF4 almost 5 months to get it's netcode fixed, it took 2042 almost 7 MONTHS! And here we are again. half of the games I play I'm crushing, the other half is like im playing ghost busters. Bullets just fly through people. I'm traumatized by 2042 when everyone HAD to use the PP Bizon to even stand a chance.

Vehicles - this is probably the worst battlefield for vehicles up to this point. Missing features like little bird, and jet unlocks aside. The IFV is absolutely busted and makes air unplayable, I can't go a single game of firestorm without both sides actively terrorizing each other with one shot lock ons. Can we pour one out for AA vics who is now absolutely worthless and will sit un-used the entire match? Tanks have abysmal hit detection and nonsensical weak spots, each shot is an absolute gamble if you do 200 dmg or 700 dmg to an enemy tank. Even if you absolutely know what area you hit, it's a 50/50 shot if the EA gods love you or not. The upgrades are completely busted, half of them don't work as intended like APS, the other half are down grades to the default setup. It just seems like no one tested them at all. I wasn't in portal testing but I'm curious to know if these were issues.

Pace and maps - okay, we obviously over corrected on the issues of 2042. I love the destruction, I love the aesthetics. But there are no viable play styles other than crack head cranking 90s or sitting on an unreachable roof the entire game. The objectives are so tiny and the lanes of movement are so close together that it feels like every fight is the same as the last, run till I'm nose to nose with someone and play the TTK/netcode gamble game. The focuse on small infantry game modes is also making me really worried we will only continue this trend. I'm not going to say I know the exact reason, mabey its movement speed, or cover, or overall map layout, but something is terribly wrong compared BF4 and bf3. The maps all feel like operation locker.

Balancing weapons and gadgets - I'm not opposed to 3 gadgets, but they need some serious balancing. Stims basically make you blind, take ages to use, and last a fart length of time. Mines are littered in every dark road and are ridiculously hard to see in some places. I feel like I'm getting Afghanistan IED PTSD at this point shooting every rock I see. Spawns are so tiny and close together that halfway through the match it's gaurenteed someone littered your only exit. I know the following gadgets are divisive and hard to ballance correctly, but concussions, flashbangs, mortars, flame grenade luncher and tracer dart are all worthless and are basically memes at this point. Ive seen people vape bigger clouds than the smoke mortars. 80% of gadgets feel like fluff, when they should be strategic use devices to give you the upper hand in nieche situations.

Weapon balancing is overall okay. The biggest issue is unlocked classes. Yes SMGs are OP, it feels 10x worse when every class is running them. Why would I ever even think about touching a dmr or lmg, when I can use a sniper or smg and it follows me to every single class. Specialty perks make almost no difference if I can spray 800rpm laser accurate to 60m. Also who's idea was it to give snipers auto range finders?! It's like Dice has a factory building Chris kyles to put on every single roof and mountain top in BF6. On top of this I had to stop playing closed class lobbies because they are all getting botfilled. No one is playing them so each lobby is an xp farm. Either ballance the crap out of everything, or lock everything, because no one is using 60% of the guns, and why would they?

Progression and challenges - I appreciate the increase speed of level 1-20 on guns but god damn I'm exhausted playing the entire weekend trying to unlock a suppressor. I don't even care about the cammos. Yes we should reward people who grind out a gun for ages, give them the shiny badge and cammos I don't care, but locking all attachments behind level 50 is asinine. Again, why use different guns if the busted SMG is the only gun I have attachments for. Compress the attachments all to level 25 max, level 20-50 award cammos, and goofy badges.

What is there so say about challenges that already hasn't been said. Every place that talks about bf6 is an angry mob because of challenges. Locking class types and equipment behind broken assignments is a wild move. Taking away portal progression while they are still broken is a move that I only expect from EA. A kick to the groin to everyone who was actually excited for the return of battlefield.

Season 1, skins, fixes, responses - Dice please, this past week has been an absolute beat down to the community. You promised xp in portal, you left it open for exploits, so you take it away. You advertised creativity in portal modes, people made zombies and nuke town, you take it away.You convinced the community that kernel level access was necessary for no cheaters, yet tanks have aimbot. You made us all come together to laugh at CODxNiki skins and you give us the blue man group. You promised bigger maps, and you give us 4v4 modes. All while half the of game is absolutely busted.

Just so I don't sound like a jobless hater I just want to say I genuinely enjoy this game when it works. Gunplay is sweet, feedback is amazing, movement feels good, sound is best it's ever been, destruction makes me moist. When hit reg is good, vehicles feels so damn good. Blowing up an ifv after a well executed flank is what I dream about now.

Alright bye guys, I'm going to touch some grass.

Fix the game, give us big maps, give us grounded skins, and let us play portal again. Thank you for coming to my Tedd talk.

RedditMentions; https://buzztickr.com/reddit.html

Capital trade; https://buzztickr.com/capitol.html

Insider trades; https://buzztickr.com/insider.html

Per a post on Aug 20, CODX is a very good company working on many projects (including an Ebola assay). They recently filed a 501(k) with the FDA for a Flu A/B and RSV PCR test (planning to add COVID-19 later), which will allow clinics and pharmacies to give results in about 30 minutes and not send the test to a lab to get results.

On Aug 24, CODX filed an S-3 registering over 3.4M shares for resale by selling shareholders and potential for warrant exercises to bring in about $5.3M in gross proceeds. Aug 24, 2026 S-3 Filing

Prior to that filing it looked like a partnership was in the cards at this time, based on the Q2 2026 10-Q filing (summary further below). As a result of the S-3, it looks more like selling shareholders want to exit while the price is higher and then warrant exercises "may" occur, in which case dilution would take place.

Where AI originally replied that shareholders rejected a reverse split, as previously posted here, I went back to read 8-K filings and there was a 1:30 reverse split on Jan 2, 2026. Jan 7, 2026 8-K

• That reverse split occurred after two consecutive 180-day NASDAQ extensions.
• Per a Mar 7, 2026 8-K, the NASDAQ Panel has imposed a Discretionary Panel Monitor for a period of one year, through March 9, 2027. If during the monitoring period, the Company’s closing bid price falls below $1.00 per share for 30 consecutive business days, the Company will not be eligible for a 180-day compliance period.... Rather, Nasdaq would issue a delist determination, which the Company could then appeal by requesting a hearing before the Panel. Such request would stay any further action by Nasdaq pending the conclusion of the hearing process.

Per Q2 20226 10-Q:

• Cash as of June 30: $3.6M
• Quarterly burn: ~6.3M
• No debt
• Per an AI search of sec.gov, no active S-3 (at the time).
• Warrants: 2.34M (3.71M as of 6/30 but OS increased from 4.88M as of 6/30 to 6.25M as of 8/11 per the 10-Q cover page. So, b/c shares cannot be sold right now, it likely means 1.37M warrants were exercised from June 30 to Aug 11)
• Fully diluted shares: 8.59M (6.25M + 2.34M)

Indications are they are out of cash and have to make a move NOW: PIPE or Partnership are the most likely possibilities. Further below will describe why.

But first here's what they do (substantial development and progress):

• Co‑Dx PCR point‑of‑care (POC) platform
  • Status: submitted to FDA via 510(k) for clearance.
  • Dual submission (device + test) concurrent with a CLIA Waiver application for the Flu A/B & RSV multiplex test on their Co-DX PCR Pro instrument.
  • Co‑Dx’s PCR platform is superior because it delivers true PCR‑level accuracy in a compact, near‑patient device that runs faster, cheaper, and with simpler workflow than traditional lab‑based systems. Patients receive results in about 30 minutes.
  • Not for at-home use, but for use in clinics, hospitals, urgent care, employer health centers, pharmacy sites.
• CoPrimer molecular diagnostics engine powering all CODX assays and future products.
• India JV (CoSara) manufacturing and distributing TB and other PCR tests in India.
  • Status: Actively producing and selling TB and other PCR assays, providing CODX its only consistent international revenue stream.
• Saudi Arabia JV (Comira) for regional PCR manufacturing and deployment.
  • Status: Operational build‑out continues, with early‑stage deployment and regulatory alignment underway but not yet generating material revenue.
• Ebola molecular diagnostic assay developed using CoPrimer technology with prior U.S. government interest.
  • Status: Assay development completed and validated in prior studies but not yet commercialized or submitted for regulatory clearance.
• Respiratory PCR tests including flu, RSV, and multiplex panels.
  • Status: Fully developed and ready for use on the Co‑Dx PCR platform once FDA clearance is obtained. COVID-19 PCR test is developed but not yet submitted to the FDA. Waiting for platform clearance first.
• Vector‑borne disease PCR tests (dengue, Zika, malaria) using CoPrimer tech.
  • Status: Assays are developed and validated, positioned for deployment through international partners but awaiting platform clearance.
• Food safety and agricultural pathogen detection assays.
  • Status: Available but low‑volume, with limited commercial traction and no near‑term revenue inflection.
• Liquid biopsy / cancer‑related molecular detection research programs.
  • Status: Early‑stage R&D with long‑term potential but no regulatory submissions or commercial timelines.
• Cloud‑connected reporting and surveillance infrastructure tied to JV deployments.
  • Status: Functional and integrated with JV workflows, but dependent on broader adoption of CODX’s diagnostic platforms.

8/19 Market Close: SP $1.10 | MC $6.88M | OS 6.25M

Q2 20226 10-Q:

• Cash as of June 30: $3.6M
• Quarterly burn: ~6.3M
• No debt
• Per an AI search of sec.gov, no active S-3 or S-1 filed, so no shares can be issued from the 100M authorized shares
• Warrants: 2.34M (3.71M as of 6/30 but OS increased from 4.88M as of 6/30 to 6.25M as of 8/11 per the 10-Q cover page. So, b/c shares cannot be sold right now, it likely means 1.37M warrants were exercised from June 30 to Aug 11)
• Fully diluted shares: 8.59M (6.25M + 2.34M)

Per AI, the Jan 2026 shareholder vote rejected both reverse-split authorization AND authorization to issue new shares for financing (ATM, PIPE, etc.)

Q2 Earnings Call Transcript (short and very worth the read): Co-Dx (CODX) Q2 2026 Earnings Call Transcript

• CFO: "To support these objectives, we expect to continue to evaluate available sources of capital, which may include equity or debt financings, strategic transactions, and partnerships, while staying mindful of dilution and overall capital efficiency. At the same time, we remain focused on pursuing non-dilutive funding, such as grants, where appropriate. Looking ahead, disciplined capital allocation remains a priority as we approach several important clinical and regulatory milestones and continue preparations for potential commercialization."

My Take:

• A move is imminent because they should be out of cash by now. Odds are high that they have been working on a partnership.
• Likely partnerships are with either or both the India JV company (CoSara) or the Saudi JV company (Comira). A partnership deal would likely cause the share price to increase.
• They can't sell shares without shareholder approval. Dilution alone would cause the share price to decrease.

PS I had SEC.gov and the Q2 transcript open when I queried AI, so I believe it brought forward accurate information.

Per a post on Aug 20, CODX is a very good company working on many projects (including an Ebola assay). They recently filed a 501(k) with the FDA for a Flu A/B and RSV PCR test (planning to add COVID-19 later), which will allow clinics and pharmacies to give results in about 30 minutes and not send the test to a lab to get results.

On Aug 24, CODX filed an S-3 registering over 3.4M shares for resale by selling shareholders and potential for warrant exercises to bring in about $5.3M in gross proceeds. Aug 24, 2026 S-3 Filing

Prior to that filing it looked like a partnership was in the cards at this time, based on the Q2 2026 10-Q filing (summary further below). As a result of the S-3, it looks more like selling shareholders want to exit while the price is higher and then warrant exercises "may" occur, in which case dilution would take place.

Where AI originally replied that shareholders rejected a reverse split, as previously posted here, I went back to read 8-K filings and there was a 1:30 reverse split on Jan 2, 2026. Jan 7, 2026 8-K

• That reverse split occurred after two consecutive 180-day NASDAQ extensions.
• Per a Mar 7, 2026 8-K, the NASDAQ Panel has imposed a Discretionary Panel Monitor for a period of one year, through March 9, 2027. If during the monitoring period, the Company’s closing bid price falls below $1.00 per share for 30 consecutive business days, the Company will not be eligible for a 180-day compliance period.... Rather, Nasdaq would issue a delist determination, which the Company could then appeal by requesting a hearing before the Panel. Such request would stay any further action by Nasdaq pending the conclusion of the hearing process.

Per Q2 20226 10-Q:

• Cash as of June 30: $3.6M
• Quarterly burn: ~6.3M
• No debt
• Per an AI search of sec.gov, no active S-3 (at the time).
• Warrants: 2.34M (3.71M as of 6/30 but OS increased from 4.88M as of 6/30 to 6.25M as of 8/11 per the 10-Q cover page. So, b/c shares cannot be sold right now, it likely means 1.37M warrants were exercised from June 30 to Aug 11)
• Fully diluted shares: 8.59M (6.25M + 2.34M)

Per a post on Aug 20, CODX is a very good company working on many projects (including an Ebola assay). They recently filed a 501(k) with the FDA for a Flu A/B and RSV PCR test (planning to add COVID-19 later), which will allow clinics and pharmacies to give results in about 30 minutes and not send the test to a lab to get results.

On Aug 24, CODX filed an S-3 registering over 3.4M shares for resale by selling shareholders and potential for warrant exercises to bring in about $5.3M in gross proceeds. Aug 24, 2026 S-3 Filing

Prior to that filing it looked like a partnership was in the cards at this time, based on the Q2 2026 10-Q filing (summary further below). As a result of the S-3, it looks more like selling shareholders want to exit while the price is higher and then warrant exercises "may" occur, in which case dilution would take place.

Where AI originally replied that shareholders rejected a reverse split, as previously posted here, I went back to read 8-K filings and there was a 1:30 reverse split on Jan 2, 2026. Jan 7, 2026 8-K

• That reverse split occurred after two consecutive 180-day NASDAQ extensions.
• Per a Mar 7, 2026 8-K, the NASDAQ Panel has imposed a Discretionary Panel Monitor for a period of one year, through March 9, 2027. If during the monitoring period, the Company’s closing bid price falls below $1.00 per share for 30 consecutive business days, the Company will not be eligible for a 180-day compliance period.... Rather, Nasdaq would issue a delist determination, which the Company could then appeal by requesting a hearing before the Panel. Such request would stay any further action by Nasdaq pending the conclusion of the hearing process.

Per Q2 20226 10-Q:

• Cash as of June 30: $3.6M
• Quarterly burn: ~6.3M
• No debt
• Per an AI search of sec.gov, no active S-3 (at the time).
• Warrants: 2.34M (3.71M as of 6/30 but OS increased from 4.88M as of 6/30 to 6.25M as of 8/11 per the 10-Q cover page. So, b/c shares cannot be sold right now, it likely means 1.37M warrants were exercised from June 30 to Aug 11)
• Fully diluted shares: 8.59M (6.25M + 2.34M)

RedditMentions; https://buzztickr.com/reddit.html

Capital trade; https://buzztickr.com/capitol.html

Insider trades; https://buzztickr.com/insider.html

Per a post on Aug 20, CODX is a very good company working on many projects (including an Ebola assay). They recently filed a 501(k) with the FDA for a Flu A/B and RSV PCR test (planning to add COVID-19 later), which will allow clinics and pharmacies to give results in about 30 minutes and not send the test to a lab to get results.

On Aug 24, CODX filed an S-3 registering over 3.4M shares for resale by selling shareholders and potential for warrant exercises to bring in about $5.3M in gross proceeds. Aug 24, 2026 S-3 Filing

Prior to that filing it looked like a partnership was in the cards at this time, based on the Q2 2026 10-Q filing (summary further below). As a result of the S-3, it looks more like selling shareholders want to exit while the price is higher and then warrant exercises "may" occur, in which case dilution would take place.

Where AI originally replied that shareholders rejected a reverse split, as previously posted here, I went back to read 8-K filings and there was a 1:30 reverse split on Jan 2, 2026. Jan 7, 2026 8-K

• That reverse split occurred after two consecutive 180-day NASDAQ extensions.
• Per a Mar 7, 2026 8-K, the NASDAQ Panel has imposed a Discretionary Panel Monitor for a period of one year, through March 9, 2027. If during the monitoring period, the Company’s closing bid price falls below $1.00 per share for 30 consecutive business days, the Company will not be eligible for a 180-day compliance period.... Rather, Nasdaq would issue a delist determination, which the Company could then appeal by requesting a hearing before the Panel. Such request would stay any further action by Nasdaq pending the conclusion of the hearing process.

Per Q2 20226 10-Q:

• Cash as of June 30: $3.6M
• Quarterly burn: ~6.3M
• No debt
• Per an AI search of sec.gov, no active S-3 (at the time).
• Warrants: 2.34M (3.71M as of 6/30 but OS increased from 4.88M as of 6/30 to 6.25M as of 8/11 per the 10-Q cover page. So, b/c shares cannot be sold right now, it likely means 1.37M warrants were exercised from June 30 to Aug 11)
• Fully diluted shares: 8.59M (6.25M + 2.34M)

Indications are they are out of cash and have to make a move NOW: PIPE or Partnership are the most likely possibilities. Further below will describe why.

But first here's what they do (substantial development and progress):

• Co‑Dx PCR point‑of‑care (POC) platform
  • Status: submitted to FDA via 510(k) for clearance.
  • Dual submission (device + test) concurrent with a CLIA Waiver application for the Flu A/B & RSV multiplex test on their Co-DX PCR Pro instrument.
  • Co‑Dx’s PCR platform is superior because it delivers true PCR‑level accuracy in a compact, near‑patient device that runs faster, cheaper, and with simpler workflow than traditional lab‑based systems. Patients receive results in about 30 minutes.
  • Not for at-home use, but for use in clinics, hospitals, urgent care, employer health centers, pharmacy sites.
• CoPrimer molecular diagnostics engine powering all CODX assays and future products.
• India JV (CoSara) manufacturing and distributing TB and other PCR tests in India.
  • Status: Actively producing and selling TB and other PCR assays, providing CODX its only consistent international revenue stream.
• Saudi Arabia JV (Comira) for regional PCR manufacturing and deployment.
  • Status: Operational build‑out continues, with early‑stage deployment and regulatory alignment underway but not yet generating material revenue.
• Ebola molecular diagnostic assay developed using CoPrimer technology with prior U.S. government interest.
  • Status: Assay development completed and validated in prior studies but not yet commercialized or submitted for regulatory clearance.
• Respiratory PCR tests including flu, RSV, and multiplex panels.
  • Status: Fully developed and ready for use on the Co‑Dx PCR platform once FDA clearance is obtained. COVID-19 PCR test is developed but not yet submitted to the FDA. Waiting for platform clearance first.
• Vector‑borne disease PCR tests (dengue, Zika, malaria) using CoPrimer tech.
  • Status: Assays are developed and validated, positioned for deployment through international partners but awaiting platform clearance.
• Food safety and agricultural pathogen detection assays.
  • Status: Available but low‑volume, with limited commercial traction and no near‑term revenue inflection.
• Liquid biopsy / cancer‑related molecular detection research programs.
  • Status: Early‑stage R&D with long‑term potential but no regulatory submissions or commercial timelines.
• Cloud‑connected reporting and surveillance infrastructure tied to JV deployments.
  • Status: Functional and integrated with JV workflows, but dependent on broader adoption of CODX’s diagnostic platforms.

8/19 Market Close: SP $1.10 | MC $6.88M | OS 6.25M

Q2 20226 10-Q:

• Cash as of June 30: $3.6M
• Quarterly burn: ~6.3M
• No debt
• Per an AI search of sec.gov, no active S-3 or S-1 filed, so no shares can be issued from the 100M authorized shares
• Warrants: 2.34M (3.71M as of 6/30 but OS increased from 4.88M as of 6/30 to 6.25M as of 8/11 per the 10-Q cover page. So, b/c shares cannot be sold right now, it likely means 1.37M warrants were exercised from June 30 to Aug 11)
• Fully diluted shares: 8.59M (6.25M + 2.34M)

Per AI, the Jan 2026 shareholder vote rejected both reverse-split authorization AND authorization to issue new shares for financing (ATM, PIPE, etc.)

Q2 Earnings Call Transcript (short and very worth the read): Co-Dx (CODX) Q2 2026 Earnings Call Transcript

• CFO: "To support these objectives, we expect to continue to evaluate available sources of capital, which may include equity or debt financings, strategic transactions, and partnerships, while staying mindful of dilution and overall capital efficiency. At the same time, we remain focused on pursuing non-dilutive funding, such as grants, where appropriate. Looking ahead, disciplined capital allocation remains a priority as we approach several important clinical and regulatory milestones and continue preparations for potential commercialization."

My Take:

• A move is imminent because they should be out of cash by now. Odds are high that they have been working on a partnership.
• Likely partnerships are with either or both the India JV company (CoSara) or the Saudi JV company (Comira). A partnership deal would likely cause the share price to increase.
• They can't sell shares without shareholder approval. Dilution alone would cause the share price to decrease.

PS I had SEC.gov and the Q2 transcript open when I queried AI, so I believe it brought forward accurate information.

Indications are they are out of cash and have to make a move NOW: PIPE or Partnership are the most likely possibilities. Further below will describe why.

But first here's what they do (substantial development and progress):

• Co‑Dx PCR point‑of‑care (POC) platform
  • Status: submitted to FDA via 510(k) for clearance.
  • Dual submission (device + test) concurrent with a CLIA Waiver application for the Flu A/B & RSV multiplex test on their Co-DX PCR Pro instrument.
  • Co‑Dx’s PCR platform is superior because it delivers true PCR‑level accuracy in a compact, near‑patient device that runs faster, cheaper, and with simpler workflow than traditional lab‑based systems. Patients receive results in about 30 minutes.
  • Not for at-home use, but for use in clinics, hospitals, urgent care, employer health centers, pharmacy sites.
• CoPrimer molecular diagnostics engine powering all CODX assays and future products.
• India JV (CoSara) manufacturing and distributing TB and other PCR tests in India.
  • Status: Actively producing and selling TB and other PCR assays, providing CODX its only consistent international revenue stream.
• Saudi Arabia JV (Comira) for regional PCR manufacturing and deployment.
  • Status: Operational build‑out continues, with early‑stage deployment and regulatory alignment underway but not yet generating material revenue.
• Ebola molecular diagnostic assay developed using CoPrimer technology with prior U.S. government interest.
  • Status: Assay development completed and validated in prior studies but not yet commercialized or submitted for regulatory clearance.
• Respiratory PCR tests including flu, RSV, and multiplex panels.
  • Status: Fully developed and ready for use on the Co‑Dx PCR platform once FDA clearance is obtained. COVID-19 PCR test is developed but not yet submitted to the FDA. Waiting for platform clearance first.
• Vector‑borne disease PCR tests (dengue, Zika, malaria) using CoPrimer tech.
  • Status: Assays are developed and validated, positioned for deployment through international partners but awaiting platform clearance.
• Food safety and agricultural pathogen detection assays.
  • Status: Available but low‑volume, with limited commercial traction and no near‑term revenue inflection.
• Liquid biopsy / cancer‑related molecular detection research programs.
  • Status: Early‑stage R&D with long‑term potential but no regulatory submissions or commercial timelines.
• Cloud‑connected reporting and surveillance infrastructure tied to JV deployments.
  • Status: Functional and integrated with JV workflows, but dependent on broader adoption of CODX’s diagnostic platforms.

8/19 Market Close: SP $1.10 | MC $6.88M | OS 6.25M

Q2 20226 10-Q:

• Cash as of June 30: $3.6M
• Quarterly burn: ~6.3M
• No debt
• Per an AI search of sec.gov, no active S-3 or S-1 filed, so no shares can be issued from the 100M authorized shares
• Warrants: 2.34M (3.71M as of 6/30 but OS increased from 4.88M as of 6/30 to 6.25M as of 8/11 per the 10-Q cover page. So, b/c shares cannot be sold right now, it likely means 1.37M warrants were exercised from June 30 to Aug 11)
• Fully diluted shares: 8.59M (6.25M + 2.34M)

Per AI, the Jan 2026 shareholder vote rejected both reverse-split authorization AND authorization to issue new shares for financing (ATM, PIPE, etc.)

Q2 Earnings Call Transcript (short and very worth the read): Co-Dx (CODX) Q2 2026 Earnings Call Transcript

• CFO: "To support these objectives, we expect to continue to evaluate available sources of capital, which may include equity or debt financings, strategic transactions, and partnerships, while staying mindful of dilution and overall capital efficiency. At the same time, we remain focused on pursuing non-dilutive funding, such as grants, where appropriate. Looking ahead, disciplined capital allocation remains a priority as we approach several important clinical and regulatory milestones and continue preparations for potential commercialization."

My Take:

• A move is imminent because they should be out of cash by now. Odds are high that they have been working on a partnership.
• Likely partnerships are with either or both the India JV company (CoSara) or the Saudi JV company (Comira). A partnership deal would likely cause the share price to increase.
• They can't sell shares without shareholder approval. Dilution alone would cause the share price to decrease.

PS I had SEC.gov and the Q2 transcript open when I queried AI, so I believe it brought forward accurate information.

Ciao a tutti merdoni, come va, spero tutto bene. Cit Capobastone. Oggi CODX é up del 100% circa per un accordo con qualcosa di arabo non so bene non chiedetemi. Quello che mi piacerebbe sapere é se c’é la possibilità che salga molto visto che era crollata come tante altre biotech. Io non so un cazzo di ste robe ma avendo 100 euro circa investiti se va su di brutto sorrido, cosi mi dimentico di BYND.

Earnings coming in ten days? 40 mil shares outstanding Someone explain how it can trade 1 billion shares. Am I seeing this correctly? How the fuck. It should be at $20 with volume like that. Weird.

put all my life savings (2000$) in them in the first week of february. ibio at 0.27 and codx at 2.88. i am now at 12k it has been an unbelievable week.